Section Arrow
Quote
ALNY.NASDAQ
- Alnylam Pharmaceuticals
Quotes are at least 15-min delayed:2026/06/24 03:41 EDT
Regular Hours
Last
 288.18
+1.77 (+0.62%)
Day High 
291.95 
Prev. Close
286.41 
1-M High
310.53 
Volume 
1.09M 
Bid
--
Ask
--
Day Low
285.26 
Open
290.89 
1-M Low
273.11 
Market Cap 
38.24B 
Currency 美元 
P/E 72.41 
%Yield -- 
10-SMA 287.02 
20-SMA 292.34 
50-SMA 299.85 
52-W High 495.55 
52-W Low 273.11 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
3.98/13.59
Enterprise Value
39.47B
Balance Sheet
Book Value Per Share
8.05
Cash Flow
Cash Flow Yield
0.02
Income Statement
Total Revenue
3.71B
Operating Revenue Per Share
12.91
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.0417+0.0225+117.19%-- 
BOLDBoundless Bio2.6+1.2+85.71%-- 
HUMAHumacyte0.7004-0.1389-16.55%-- 
IOVAIovance Biotherapeutics4.44+0.38+9.36%-- 
GOSSGossamer Bio0.1714+0.0072+4.38%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercialRNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.